Drugs / CAR-T cells targeting CD19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04740203 | Jan 2021 → Jan 2024 | B-cell adult acute lymphocytic leukemia | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T cells targeting CD19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740203 ↗ |
| Modality | Cell therapy | “CAR-T cells targeting CD19 and CD22” NCT04740203 ↗ |
| Route | Intravenous | “Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion” NCT04740203 ↗ |